Surufatinib

Generic Name: Surufatinib

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₈N_₆O_₃S

CAS Number: 1308672-74-3

Unique Ingredient Identifier: B2K5L1L8S9

Background: Surufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).

Indication: 单药用于治疗无法手术切除的局部晚期或转移性、进展期非功能性、分化良好（G1、G2）的胰腺和非胰腺来源的神经内分泌瘤（pNETs）。

Clinical Trials

Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

Phase 2

Recruiting

Conditions: Advanced Biliary Tract Cancer

Interventions: Drug: Surufatinib
Drug: Gemcitabine
Drug: Cisplatin
Drug: Durvalumab
Drug: Pembrolizumab

First Posted Date: 2024-11-27

Last Posted Date: 2024-11-27

Lead Sponsor: Dai, Guanghai

Target Recruit Count: 35

Registration Number: NCT06708858

Locations: 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

Phase 2

Not yet recruiting

Conditions: ESCC
Biliary Tract Cancer
Gastric Cancer
Pancreas Cancer

Interventions: Drug: Surufatinib
Drug: Serplulimab
Drug: standard chemotherapy

First Posted Date: 2024-07-31

Last Posted Date: 2024-07-31

Lead Sponsor: RenJi Hospital

Target Recruit Count: 80

Registration Number: NCT06531291

Locations: 🇨🇳
Renji hospital, Shanghai, Shanghai, China

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2

Not yet recruiting

Conditions: Gastric Cancer
Gastro Esophageal Junction Cancer

Interventions: Drug: Surufatinib
Drug: Sintilimab
Drug: Oxaliplatin
Drug: S1

First Posted Date: 2024-06-07

Last Posted Date: 2024-06-07

Lead Sponsor: Fudan University

Target Recruit Count: 20

Registration Number: NCT06447636

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, China

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

Phase 2

Not yet recruiting

Conditions: NSCLC

Interventions: Drug: Surufatinib
Drug: Tislelizumab

First Posted Date: 2024-05-16

Last Posted Date: 2024-05-16

Lead Sponsor: National Cancer Center, China

Target Recruit Count: 29

Registration Number: NCT06414915

The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Surufatinib combine immune checkpoint inhibitor
Drug: AG/FOLFIRINOX

First Posted Date: 2024-04-22

Last Posted Date: 2024-04-22

Lead Sponsor: Luo Cong

Target Recruit Count: 72

Registration Number: NCT06378580

Locations: 🇨🇳
Zhejiang Province Cancer Hospital, Hangzhou, Zhejiang, China

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Phase 2

Recruiting

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine
Drug: Nab-paclitaxel Plus Gemcitabine
Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine

First Posted Date: 2024-04-12

Last Posted Date: 2024-05-14

Lead Sponsor: Hutchmed

Target Recruit Count: 482

Registration Number: NCT06361888

Locations: 🇨🇳
Nanjing Tianyinshan Hospital, Nanjing, Jiang Su, China
🇨🇳
Tianjin Cancer Hospital, Tianjin, Tianjin, China

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Phase 2

Not yet recruiting

Conditions: Pancreatic Cancer
Pancreatic Cancer Non-resectable
Pancreatic Ductal Adenocarcinoma, PDAC

Interventions: Drug: surufatinib combined with gemcitabine plus nab-paclitaxel

First Posted Date: 2024-04-11

Last Posted Date: 2024-04-11

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 40

Registration Number: NCT06361030

Locations: 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD

Phase 2

Not yet recruiting

Conditions: Advanced Pancreatic Cancer

Interventions: Drug: Surufatinib 250mg/d qd once daily

First Posted Date: 2024-03-26

Last Posted Date: 2024-05-08

Lead Sponsor: Rui-hua Xu, MD, PhD

Target Recruit Count: 37

Registration Number: NCT06329947

Locations: 🇨🇳
SunYat-senUniversity Cancer Center, Guangzhou, China

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Phase 1

Not yet recruiting

Conditions: Biliary Tract Cancer

Interventions: Drug: Surufatinib
Drug: Durvalumab

First Posted Date: 2024-02-13

Last Posted Date: 2024-02-13

Lead Sponsor: China Medical University, China

Target Recruit Count: 30

Registration Number: NCT06255262

Locations: 🇨🇳
Anshan Cancer Hospital, Anshan, Liaoning, China
🇨🇳
The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
🇨🇳
First Hospital of China Medical University, Shenyang, Liaoning, China

and more 1 locations

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Phase 2

Active, not recruiting

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: HAIC+TAE
Drug: Tislelizumab
Drug: Surufatinib

First Posted Date: 2024-02-02

Last Posted Date: 2024-11-21

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 28

Registration Number: NCT06239532

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy